Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Summary

Q32 Bio announced the pricing of a $200 million underwritten public offering of common stock and pre-funded warrants. The clinical-stage biotechnology company is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases.